The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
AS. The Optipharm products are already on supermarket shelves in the area covered by FSANZ .
Just not enough shelf space.
It is ‘chicken and egg’ situation and would be helped enormously by prominent claim space on packaging.
martini,
Simply, irrespective of whether you currently own you Opti shares, you still hold 12p worth of PBX shares (at their 21.5p) on your behalf until released.
My interpretation of that is the current price of Opti shares does not include any value of your PBX.
Subject to wiser heads!
Some thoughts on PBX exiting from its lock in until 2023. Holders of OPTI who have sold by then will still hold a nominal 12p value in PBX which can be traded.
I find it difficult to see the outcome unless Probiotix manages to execute some significant revenue by Jan 2023 and Opti also generates revenue out of its Promised Land.
Interesting and I still suspect there may be some progress.
On previous year experience, we should expect the ‘very late’(my view) 2021 Annual Report which should include a comprehensive expectation of 2022. At this time SOH already has most of the H1 data to make this data very accurate.
So I am calling on the company to finally get its act together. Overall the company has had £2m
extra cash plus Probiotix should be utilising the cash raised in its float three months ago
Logically the current Opti share price reflects the full value of the future PBX held on behalf.
Perhaps as the issue comes into access in 2023, then the value may hold up without any significant drop in Opti shares.
Finally the underlying value of the whole portfolio may become more accepted by the market.
I accept that the market price of PBX could help from the outside. ??
Yes, I live just down the road from the publisher of Eastlife.
Bioslim is an Australian marketer of product and uses Slimbiome but I have not been able to source any other products such as snack bars so far. They obviously intend to do so as I have read such. They have one advantage over Optipharm as they market through a range of pharmacies and not just a major supermarket and chemist chain.
I will advise any further developments as they come available.